Pharm'Up 
A new study published in JAMA Pediatrics has uncovered why some children with asthma continue to suffer from flare-ups even while on treatment. The research suggests that by suppressing one type of inflammatory response, current therapies may inadvertently activate other, previously overlooked pathways that drive asthma attacks. This finding points to a critical need for more personalized treatment strategies.
Asthma, particularly the severe eosinophilic type, is often linked to Type 2 (T2) inflammation. Treatments like mepolizumab are designed to target and block this specific inflammatory response. However, a key question has persisted: if these treatments are successful at what they’re designed to do, why do some children still experience debilitating asthma exacerbations?
To answer this, researchers conducted a detailed analysis of the MUPPITS-2 clinical trial. They studied nasal samples from children with asthma and used RNA sequencing to identify the specific molecular mechanisms at play during an asthma flare-up.
The findings were revealing. While mepolizumab effectively suppressed T2 inflammation, it did not stop asthma attacks in all patients. Instead, the study identified three distinct inflammatory drivers that were activated:
- Epithelial Inflammation: The lining of the airways showed increased inflammatory responses, regardless of a viral infection. This suggests that the airways themselves were still contributing to the problem.
- Macrophage-Driven Inflammation: This type of inflammation, which is closely linked to viral illnesses, was found to be a key driver of flare-ups. Given that viruses are a major trigger for asthma attacks, this is a significant finding.
- Mucus Hypersecretion: Both children on mepolizumab and those on a placebo experienced an overproduction of mucus and cellular stress during flare-ups.
Dr. Rajesh Kumar of Ann & Robert H. Lurie Children’s Hospital of Chicago explained that when a drug blocks one inflammatory pathway, other “residual epithelial pathways” can take over. This complexity highlights that asthma is not a single disease driven by one pathway, but a condition with multiple contributing factors.
The study concludes that to truly help these children, a more precise, personalized approach is needed. The findings open the door for new therapies or combinations of therapies that can target these different inflammatory drivers, leading to more effective prevention and treatment of asthma in children.
About the Author
